On Thursday, Shares of Kohl’s Corporation (NYSE:KSS), declined -0.08% to $62.41, during its last trading session.
Kohl’s Corporation, declared Michelle Gass has been designated to the newly created principal officer position of Chief Merchandising and Customer Officer. In this new capacity, Gass has assumed oversight of all of Kohl’s merchandising, planning and allocation, and product development functions. She will continue to report to Kevin Mansell, Kohl’s chairman, chief executive officer and president. Gass retains direct responsibility for Kohl’s overall customer engagement strategy, counting the company’s marketing, public relations and social media efforts. In light of Gass’ new responsibilities, Mansell has assumed direct oversight of the company’s digital and e-commerce strategies and operations.
Kohl’s has commenced an external search for a Chief Operating Officer, a newly created principal officer position. The chief operating officer will have direct responsibility for the company’s store operations, logistics and supply chain network, information and digital technology, e-commerce strategy and operations, and store construction and design. In the interim, these functions are all being overseen by Mansell. Along with Gass, the chief operating officer is predictable to be a potential candidate to succeed Mansell upon his eventual retirement.
Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers.
At the end of Thursday’s trade, Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN), gained 2.08% to $ 16.23.
Supernus Pharmaceuticals, declared that it will webcast its Investor Day presentation on June 17, 2015.
During the meeting, members of Supernus’ senior administration team will provide a detailed disucssion of the Company’s clinical programs, counting efficacy and safety results for accomplished trials of its two late stage clinical programs, plans for prospective clinical trials, and an assessment of their market opportunity. In addition, several key thought leaders will share their perspectives on the current treatment paradigms, unmet medical needs, and the Company’s clinical development programs.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its marketed products comprise Oxtellar XR, an extended-release oxcarbazepine and Trokendi XR, an extended-release topiramate, which are neurology products used for the treatment of epilepsy.
Finally, Royal Dutch Shell plc (ADR) (NYSE:RDS.A), ended its last trade with -0.07% gain, and close at $ 59.09.
Royal Dutch Shell plc’s (RDS-A) (RDS-B) capital comprises of 3,894,584,881 A shares and 2,440,410,614 B shares, each with equal voting rights. Royal Dutch Shell plc holds no ordinary shares in Treasury.
The total number of A shares and B shares in issue is 6,334,995,495 and this figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Royal Dutch Shell plc under the FSA’s Disclosure and Transparency Rules.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
